pioglitazone has been researched along with Experimental Hepatoma in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Guo, YT | 1 |
Leng, XS | 1 |
Zhao, JM | 1 |
Lin, XH | 1 |
Li, T | 1 |
Zhu, JY | 1 |
Solomon, SS | 1 |
Mishra, SK | 1 |
Cwik, C | 1 |
Rajanna, B | 1 |
Postlethwaite, AE | 1 |
2 other studies available for pioglitazone and Experimental Hepatoma
Article | Year |
---|---|
[Pexoxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats].
Topics: Animals; Antineoplastic Agents; Chromans; Diethylnitrosamine; Ligands; Liver Neoplasms, Experimental | 2005 |
Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; | 1997 |